GeneDx Swaps CEOs: Ex-Illumina Commercial Chief Cunningham Takes Over by December 15
WGS sits 47% above its 52-week low of $32.21 on elevated volume (2.4× avg).
Summary
GeneDx named Everett Cunningham CEO effective on or before December 15, 2026, replacing Katherine Stueland, who steps off the board and stays as an advisor through January 31, 2027. Cunningham's package includes a $750,000 base salary, a $1.05M sign-on bonus, $10M in time-vested RSUs and $10M in performance RSUs. He is a diagnostics commercial operator — most recently CEO of Quanterix, before that chief commercial officer at Illumina and Exact Sciences, plus senior roles at GE Healthcare, Quest Diagnostics and Pfizer. The board is betting on commercial execution: Chairman Keith Meister framed the hire around moving exome and genome sequencing from early adoption to standard of care. The timing is notable — this follows the November 9 Q3 report where revenue rose 5% to $123.1M but adjusted net income fell to $8.6M from $16.1M, and the November 10 guidance cut that sent shares lower. Management reaffirmed full-year 2026 guidance as provided on November 9, so the transition does not come with a numbers reset. Cunningham also sits on the board of Arvinas (ARVN), the second ticker tagged here; that company is not a party to this announcement and is unaffected operationally.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Cunningham gets a $750,000 base salary, $1.05M sign-on bonus, $10M time-vested RSUs and $10M performance RSUs; Stueland stays as advisor through January 31, 2027.
At the time of this announcement, WGS was trading at $47.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.